Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to work with patients diagnosed with end-stage liver disease to understand their perspectives on the Health at Home (H@H) Program, including desired outcomes and expectations, perceived barriers, and drivers. H@H is an emerging model of home-based care, designed to extend traditional, inpatient hospital care which may address these needs. Through H@H, acute medical care services as well as ancillary care such as rehabilitation therapy can be delivered in the home. The study is divided into three phases: Phase 1 occurs while the participant is an inpatient. Phase 2 is when the actual H@H program takes place as part of the participant's clinical care. The study team will not be involved in the Phase 2 - H@H program as it will be conducted by the clinical staff. Phase 3, at which point the participant enters a rehabilitation phase to transition the patient to self-management, involves a research jam session with the participant and caregiver to assess the value of the program.


Clinical Trial Description

Hospital at Home (H@H) as an emerging model of care is designed as an extension for traditional inpatient hospital care. Patients experiencing certain medical conditions normally requiring admission to an inpatient hospital can instead consent to receive acute care treatment in their homes. Prior studies have shown success of this model through demonstration of clinical and economic efficacy and feasibility, as well as greater satisfaction with care for patients, their family members and their providers. Since November 2020, Centers for Medicare and Medicaid Services has provided a waiver for H@H services. Similarly in 2020, Indiana University Health (IUH) introduced the Hospital at Home (H@H) Program for its beneficiaries to increase hospital capacity during the Public Health Emergency. Through this program, primary medical management services as well as ancillary services such as Occupational Therapy, Physical Therapy, and diagnostic testing can be delivered in the home. This model has been successful used at IUH to management patients with moderate COVID-19 infection, common infectious diseases, and decompensated heart failure. In the realm of liver disease, acute decompensations of chronic liver disease often require hospitalizations for acute management. In certain clinical scenarios, while the initial 24-48 hour period may require the intensive management offered in an acute care hospital, the remaining hospital days represent less acute and/or intense needs such as continued administration of IV medications, monitoring for safe transition to oral medications and/or daily lab monitoring for period of time. We hypothesize that services through the IUH H@H program can offer equally safe and effective for these clinical scenarios while improving patient satisfaction, reducing care-giver burden, being cost-saving and improving access to acute care hospital services to other patients. We also hypothesize that completing the acute care management in the home setting will lead to more effective transition to chronic management as measured by subsequent 30-day readmissions and 30-day emergency room visits leading to reduced overall cost of health care. As a next step in expansion, the IUH H@H team is partnering with the PI and IUH Hepatology team to manage select patients with chronic liver disease (CLD). The overall goal of this proposal is to assess whether IUH's H@H program represents a novel care delivery model in cirrhosis that is safe, improves patient and caregiver experience as well as reduces HCU in the high-risk, CLD population. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06396897
Study type Observational
Source Indiana University
Contact Regia Weber
Phone 317-278-3584
Email reginaw@iu.edu
Status Recruiting
Phase
Start date May 10, 2024
Completion date December 31, 2027

See also
  Status Clinical Trial Phase
Completed NCT01701687 - Biomarkers for the Prognosis of Decompensated Alcoholic Liver Disease N/A
Recruiting NCT05121870 - Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis Phase 2
Recruiting NCT05421351 - Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF
Not yet recruiting NCT05086536 - Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
Recruiting NCT03820271 - New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation N/A
Recruiting NCT06134544 - Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis N/A
Recruiting NCT06223893 - CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis N/A
Completed NCT02219477 - A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis Phase 3
Recruiting NCT05734001 - Rotational Thromboelastometry Versus Conventional Haemostatic Tests in Children With Decompensated Cirrhosis Undergoing Invasive Procedures. N/A
Terminated NCT04775329 - Primary Prophylaxis for Spontaneous Bacterial Peritonitis Phase 2/Phase 3
Recruiting NCT04422223 - Prospective Cohort Study of Disease and Outcomes in Cirrhosis
Recruiting NCT02786017 - Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis Phase 1/Phase 2
Completed NCT01326949 - Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis N/A
Not yet recruiting NCT06306781 - A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis N/A
Recruiting NCT05227846 - Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1) Phase 1
Not yet recruiting NCT05937048 - Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D). N/A
Active, not recruiting NCT03205345 - Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis Phase 2
Terminated NCT03462576 - Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17
Not yet recruiting NCT05224960 - Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2) Phase 2
Terminated NCT04112199 - A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites Phase 2